Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05101564 · ClinicalTrials.gov registry record · Phase 2
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
A Phase 2 study of Breast Cancer and HER2-Negative Breast Cancer, sponsored by Jennifer Lee Caswell-Jin.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT05101564: Completed Phase 2 study of Breast Cancer and HER2-Negative Breast Cancer, sponsored by Jennifer Lee Caswell-Jin.
NCT05101564 is a Phase 2 study of Breast Cancer and HER2-Negative Breast Cancer that has completed, run by Jennifer Lee Caswell-Jin. The registered enrollment target is 19 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05101564, a Phase 2 study of Breast Cancer and HER2-Negative Breast Cancer, has completed, sponsored by Jennifer Lee Caswell-Jin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn if adding a new drug that is targeted at a specific genetic change found in some breast tumors pre-operatively will slow the growth of the tumor more than standard anti-hormone therapy used to treat this type of breast cancer. Different therapies are being tested based on the specific gene changes in the tumor. Not every tumor will have a gene change that is being studied.
Conditions Studied
Interventions
- DRUG Tamoxifen
- DRUG Fulvestrant
- DRUG Alpelisib
- DRUG Zotatifin
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2023-03-20 |
| Est. Completion | 2024-06-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05101564
The ClinicalTrials.gov registry entry for NCT05101564 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Jennifer Lee Caswell-Jin, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Tamoxifen is the first listed.
NCT05101564 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05101564 about?
NCT05101564 is a clinical study titled "Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer". The purpose of this study is to learn if adding a new drug that is targeted at a specific genetic change found in some breast tumors pre-operatively will slow the growth of the tumor more than standard anti-hormone therapy used to treat this type of breast cancer. Different therapies are being teste...
What is the current status of trial NCT05101564?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2023-03-20. Estimated completion is 2024-06-03.
What conditions does trial NCT05101564 study?
This clinical trial studies the following conditions: Breast Cancer, HER2-Negative Breast Cancer, ER Positive Breast Cancer.
What interventions are being tested in trial NCT05101564?
The interventions under investigation include: Tamoxifen (DRUG), Fulvestrant (DRUG), Alpelisib (DRUG), Zotatifin (DRUG).
Who is sponsoring clinical trial NCT05101564?
This trial is sponsored by Jennifer Lee Caswell-Jin, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05101564 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.